NKGen Biotech, Inc. Common Stock
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. over the previous period. Total operating expenses were $28,543,000.
Profit Margin
| 2021 | 426K | -23.26M | -5461.27% |
|---|---|---|---|
| 2022 | 77K | -26.75M | -34745.45% |
| 2023 | 0 | -82.95M |
NKGN Income Statement (2021 – 2023)
| 2023 | 2022 | 2021 | |
|---|---|---|---|
Revenue | |||
Revenue | 0 | 77K | 426K |
Cost of revenue | 1.20M | 18K | 30K |
Gross profit | -1.20M | 59K | 396K |
Operating exp. | |||
Research and development | 14.46M | 16.74M | 14.67M |
Selling and marketing | 0 | 0 | 0 |
Total operating expenses | 28.54M | 24.40M | 22.25M |
Operating income | -29.74M | -24.34M | -21.86M |
Other income (expenses), net | -53.20M | -95K | -84K |
Income before tax | -82.94M | -26.74M | -23.26M |
Income tax expense | 7K | 7K | 5K |
Net income | -82.95M | -26.75M | -23.26M |
Earnings per share | |||
Basic EPS | -5.38 | -4.21 | -1.08 |
Diluted EPS | -5.38 | -4.21 | -1.08 |